COMPANIES AstraZeneca has upgraded earnings forecasts following strong US expert endorsement of its new drug Brilinta, as it pledged increased share buy-backs and unveiled strong second-quarter results.
The Anglo-Swedish pharmaceutical group posted unchanged core operating profits of $3.7bn, with revenue growth and lower operating costs offset by lower other operating income. Sales rose 3 per cent to $8.2bn.
